Literature DB >> 26575203

Big Data and Adverse Drug Reaction Detection.

R Harpaz1, W DuMochel1, N H Shah2.   

Abstract

Big Data holds the promise of fundamentally transforming the manner in which adverse drug reactions can be identified and evaluated. This commentary discusses new data sources that are envisioned to form a Big Data-enabled pharmacovigilance system and the role of these data in powering the future of adverse drug reactions detection.
© 2015 ASCPT.

Mesh：

Year:  2015        PMID： 26575203     DOI： 10.1002/cpt.302

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  10 in total

1.  Big Data and Pharmacovigilance: Data Mining for Adverse Drug Events and Interactions.

Authors:  C Lee Ventola
Journal:  P T       Date:  2018-06

2.  Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS).

Authors:  Tristan T Timbrook; Lydia McKay; Jesse D Sutton; Emily S Spivak
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.

Authors:  Yue Yu; Kathryn J Ruddy; Na Hong; Shintaro Tsuji; Andrew Wen; Nilay D Shah; Guoqian Jiang
Journal:  J Biomed Inform       Date:  2019-02-07       Impact factor: 6.317

4.  Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators.

Authors:  Jonathan Bates; Craig S Parzynski; Sanket S Dhruva; Andreas Coppi; Richard Kuntz; Shu-Xia Li; Danica Marinac-Dabic; Frederick A Masoudi; Richard E Shaw; Frederick Warner; Harlan M Krumholz; Joseph S Ross
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-06-12       Impact factor: 2.890

5.  Frequent Adverse Drug Reactions, and Medication Groups under Suspicion.

Authors:  Diana Dubrall; Matthias Schmid; Eva Alešik; Norbert Paeschke; Julia Stingl; Bernhardt Sachs
Journal:  Dtsch Arztebl Int       Date:  2018-06-08       Impact factor: 5.594

6.  Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review.

Authors:  Faizan Mazhar; Vera Battini; Marco Pozzi; Elena Invernizzi; Giulia Mosini; Michele Gringeri; Annalisa Capuano; Cristina Scavone; Sonia Radice; Emilio Clementi; Carla Carnovale
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

7.  Risk of Pneumonia Associated With the Use of Inhaled Corticosteroids in Asthma.

Authors:  Sang Heon Kim
Journal:  Allergy Asthma Immunol Res       Date:  2019-11       Impact factor: 5.764

Review 8.  Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications.

Authors:  Zuanji Liang; Yunfeng Lai; Meng Li; Junnan Shi; Chi Ieong Lei; Hao Hu; Carolina Oi Lam Ung
Journal:  Chin Med       Date:  2021-02-16       Impact factor: 5.455

9.  Identifying Actionability as a Key Factor for the Adoption of 'Intelligent' Systems for Drug Safety: Lessons Learned from a User-Centred Design Approach.

Authors:  George I Gavriilidis; Vlasios K Dimitriadis; Marie-Christine Jaulent; Pantelis Natsiavas
Journal:  Drug Saf       Date:  2021-10-21       Impact factor: 5.606

10.  Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.

Authors:  Sunny Park; So Hyang Park; Young Joo Byun; Soo An Choi
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.